Generex Biotechnology Corporation (OTCMKTS:GNBT) concluded an immunogenicity trial in genetically engineered mice with a gene collected from the human immune system called DL4 HLA allele.
Human leukocyte antigen in the human body
The Human body possesses several HLAs (human leukocyte antigen) in most of its cells. The immune system uses hLAs or markers to detect foreign cells. Generex evaluates the efficacy of li-key vaccines through DR4 transgenic mouse trial to produce immune responses in the animal model. In this trial, the DR4 allele is recognized in just one of the several human HLA epitopes found in the Ii-Key-SARS-CoV-2 vaccine.
Generex demonstrated through this study that the li-key vaccine, together with these adjuvant generated antibodies, is directed against the LI (Ii-Key-SARS-CoV-2) epitopes. The mice’s T cells exhibited a strong reaction to the li-key vaccine stimulation in an ex vivo trial of the mouse spleen cells that comprise macrophages, dendritic cells, and T and B cells. Therefore, LI has a potential to become a complete vaccine. However, its efficacy can be confirmed through human clinical trials. A complete vaccine regulates the immune system for a neutralizing and targeted antibody response.
President of Generex, Joseph Moscato, said the company is preparing for IND submission to conduct phase II and phase I clinical trials for evaluating immunogenicity and safety of the li-key vaccine. He further said its technology provides the safest way for ensuring long-term immunity via T cell activation. The company plans to test the LI vaccine in people affected by the coronavirus previously to know if the li-key vaccine activates T cell immune response for long-term immunity.
According to the data obtained from previous clinical trials, the li-key vaccine improves long-term immune memory and safe. FDA already recognized the safety of the LI vaccine.
Generex subsidiary – NuGenerex Immuno-Oncology engages in the development of immunotherapeutic peptide vaccines to treat infectious diseases and cancer. NuGenerex Immuno-Oncology is established for advancing li-key technology platform together with immune checkpoint inhibitors to treat cancer.
At present, NuGenerex Immuno-Oncology engages in Phase II clinical study of AE37, the cancer immunotherapeutic vaccine, together with Merck’s keytruda to cure triple-negative breast cancer.